CN110327320B - A Chinese medicinal composition with leukocyte increasing effect - Google Patents
A Chinese medicinal composition with leukocyte increasing effect Download PDFInfo
- Publication number
- CN110327320B CN110327320B CN201910665998.XA CN201910665998A CN110327320B CN 110327320 B CN110327320 B CN 110327320B CN 201910665998 A CN201910665998 A CN 201910665998A CN 110327320 B CN110327320 B CN 110327320B
- Authority
- CN
- China
- Prior art keywords
- active ingredient
- chinese medicine
- traditional chinese
- ingredient composition
- increasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 22
- 230000001965 increasing effect Effects 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 16
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 16
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 16
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 16
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZTVSGQPHMUYCRS-SWLSCSKDSA-N (4as,8as)-3,8a-dimethyl-5-methylidene-4a,6,7,8-tetrahydro-4h-benzo[f][1]benzofuran-2-one Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C=C1C2=C(C)C(=O)O1 ZTVSGQPHMUYCRS-SWLSCSKDSA-N 0.000 claims abstract description 12
- OQYBLUDOOFOBPO-UHFFFAOYSA-N Asterolide Natural products C1C2C(=C)CCCC2(C)CC2C1=C(C)C(=O)O2 OQYBLUDOOFOBPO-UHFFFAOYSA-N 0.000 claims abstract description 12
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims abstract description 11
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims abstract description 11
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000009636 Huang Qi Substances 0.000 claims abstract description 3
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims 5
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims 5
- -1 AO-I Chemical compound 0.000 claims 1
- 241000125175 Angelica Species 0.000 claims 1
- 241000382455 Angelica sinensis Species 0.000 claims 1
- 241000045403 Astragalus propinquus Species 0.000 claims 1
- 241000132012 Atractylodes Species 0.000 claims 1
- 241000092665 Atractylodes macrocephala Species 0.000 claims 1
- 235000001287 Guettarda speciosa Nutrition 0.000 claims 1
- 235000006533 astragalus Nutrition 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 abstract description 13
- 238000010171 animal model Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 10
- 108010010803 Gelatin Proteins 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930003776 Vitamin B4 Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 239000011579 vitamin B4 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Abstract
The invention belongs to the technical field of traditional Chinese medicine preparations, and provides a traditional Chinese medicine active ingredient composition with a function of increasing leucocytes, aiming at solving the problems that the traditional medicine for treating leucopenia is inaccurate in treatment effect, a novel medicine is high in price and has obvious side effects and the like. The Chinese medicinal active ingredient composition with leukocyte increasing effect is prepared by mixing two or three of Ferulic Acid (FA) in radix Angelicae sinensis, astragaloside IV (AST) in radix astragali and atractylenolide I (AO-I) in Atractylodis rhizoma. The invention can obviously increase the compatibility of two or three groups under the optimal compatibilityP<0.01) the content of leucocyte and marrow DNA of the leucopenia animal model, which shows that the Chinese medicinal active ingredient composition has remarkable curative effect on treating the leucopenia and has good popularization value.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine active ingredient composition with a function of increasing leucocytes, which is used for treating leucopenia.
Background
Leukopenia refers to a sustained white blood cell count in the peripheral blood<4.0×109The syndrome/L is a common blood disease, which is mainly manifested by weakness, palpitation, dizziness, soreness and weakness of limbs, insomnia and dreaminess. When white blood cells are counted< 2.0×109Absolute value of/L, neutrophil<0.5×109At the time of/L, the symptoms of sudden headache, arthralgia, extreme weakness and the like are presented, and even the serious patient has symptoms of dysphagia and the like, and the death rate is extremely high.
The existing main treatment chemical drugs for leukopenia comprise traditional drugs of lithium carbonate and vitamin B4, a novel drug of colony stimulating factor and the like. However, the traditional medicine has an uncertain treatment effect, and the novel medicine is expensive, has obvious side effects and can only be used after 24-48 hours of chemotherapy. However, as the development of traditional Chinese medicine is receiving more and more attention, the traditional Chinese medicine has made certain progress in the treatment and clinical application research of leucopenia. Therefore, the traditional Chinese medicine or traditional Chinese medicine active ingredient composition with definite curative effect, reasonable price and low side effect is searched, and the Chinese medicine or traditional Chinese medicine active ingredient composition has important significance for the reasonable medication of clinical leucopenia and the research and development of new drugs.
Disclosure of Invention
The invention provides a traditional Chinese medicine active ingredient composition with the function of increasing leucocytes, aiming at solving the problems that the traditional medicine for treating leucopenia has uncertain treatment effect, a novel medicine is high in price and has obvious side effect and the like.
The invention is realized by the following technical scheme: a Chinese medicinal active ingredient composition with leukocyte increasing effect is prepared by mixing two or three of Ferulic Acid (FA) in radix Angelicae sinensis, astragaloside IV (AST) in radix astragali, and atractylenolide I (AO-I) in Atractylodis rhizoma.
The traditional Chinese medicine active component composition with the function of increasing the white blood cells is prepared by mixing 30-50% of FA, 25-40% of AST and 15-30% of AO-I according to mass percentage.
The traditional Chinese medicine active ingredient composition with the function of increasing the white blood cells is prepared by mixing FA, AST and AO-I according to the mass ratio of 3:2: 1.
The traditional Chinese medicine active ingredient composition with the function of increasing the white blood cells is prepared by mixing FA and AST according to the mass ratio of 3: 2.
The traditional Chinese medicine active ingredient composition with the function of increasing the white blood cells is prepared by mixing FA and AO-I according to the mass ratio of 3: 1.
The traditional Chinese medicine active ingredient composition with the function of increasing the white blood cells is prepared by mixing AO-I and AST according to the mass ratio of 1: 2.
The invention can obviously increase the compatibility of two or three groups under the optimal compatibilityP<0.01) leukocyte depletionThe leucocyte and marrow DNA content of the oligodynamic animal model, and the optimal leucocyte activity can be improved by the three groups of compatibility. The traditional Chinese medicine active component composition has obvious curative effect on treating the leucopenia and has good popularization value.
Detailed Description
In order that the objects and advantages of the invention will be more clearly understood, the invention is further described in detail below with reference to examples. The specific embodiments described herein are merely illustrative of the invention and do not delimit the invention.
ICR mice were weighed, numbered, and randomly divided into a blank control group, a model group, a single-component experimental group, a component compatibility experimental group, and a positive drug donkey-hide gelatin blood-enriching granule group (LJG). The model is made at the 1d of the experiment, the mice in the model group are injected with cyclophosphamide 80mg/kg in the abdominal cavity to establish a leukopenia model, and the normal group is given sterilizing injection water with the same volume and continuously injected for 3 days. The single component experimental group, the component compatibility experimental group and the donkey-hide gelatin blood-enriching granule group (LJG) are given corresponding drugs 7d on the basis of the model group. After 24h of the last administration, the orbital blood sampling is carried out to determine the blood routine, and the femoral bone marrow is collected to detect the bone marrow DNA content. The medicament is dissolved or suspended by adopting aqueous solution of Tween 80 and ethanol, wherein the final concentration of Tween 80 and ethanol is less than 0.1%.
TABLE 1 leukocyte content of the groups of mice: (
±s, n=12)
Note: comparison with blank control: **P<0.01, compared to the model group:# P<0.05, ## P<0.01
TABLE 2 bone marrow DNA content of mice in each group: (
±s, n=12)
Note: comparison with blank control: **P<0.01, compared to the model group:## P<0.01
mixing the three components in pairs or three groups according to the proportion to prepare a composition, comparing the monomers of the three components with the positive medicine donkey-hide gelatin blood-enriching particles, and performing leukocyte three-classification determination and bone marrow DNA content determination. As shown in tables 1 and 2, the above-mentioned components, mixed two by two or three, significantly increased the DNA content in leukocytes and bone marrow, and the effect was superior to that of the monomer administration group. The FA + AST + AO-I (3:2:1) composition shows the best treatment effect and has the same effect as the positive medicine donkey-hide gelatin blood-enriching particles.
To further demonstrate the leukocyte-increasing activity of the composition of the present invention, the proliferation effect of the composition on in vitro granulocytic hematopoietic cells was studied by hematopoietic model cell HL-60 (human granulocytic leukemia cell line), and the specific embodiment is as follows:
the effect of the composition on HL-60 cell proliferation was observed using the CCK-8 method. HL-60 cells were resuspended in IMDM medium (containing 15% FBS) at 2X 104One cell/well was inoculated into a 96-well plate, and the 96-well plate was pre-cultured in an incubator for 24 hours (37 ℃, 5% CO)2). Subsequently, groups of drugs dissolved in FBS-free IMDM medium were added to each well and incubated for 24 hours. 20 μ L of CCK-8 reagent was added to each well and cultured for 4 hours, and the absorbance at 450 nm was measured with a microplate reader to calculate the cell viability.
TABLE 3 Effect of compositions on HL-60 cell viability
Note: comparison with blank control: **P<0.01
Mixing the three components in pairs or three groups to obtain composition, and comparing the monomers of the three components with the blood-replenishing granules of donkey-hide gelatin as positive drug to perform in vitro hematopoietic cell HL-60 proliferation experiment. The results are shown in table 3, and the two-two or three-group mixture of the components can remarkably promote the proliferation of hematopoietic cells in vitro, and the effect is better than that of the monomer administration group. The FA + AST + AO-I (3:2:1) composition shows the best treatment effect and has the same effect as the positive medicine donkey-hide gelatin blood-enriching particles.
The research shows that the traditional Chinese medicine active ingredient composition can obviously improve the leukopenia caused by the chemotherapy drugs and promote the proliferation activity of the hematopoietic cells in vitro, and can be used for preparing the drugs for the leukopenia caused by clinical chemotherapy or used as the adjuvant drugs of the chemotherapy drugs.
The above description is only for the preferred embodiment of the present invention, and it should be noted that the protection scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention disclosed herein should be covered within the protection scope of the present application. Therefore, the protection scope of the present application shall be subject to the protection scope of the claims.
Claims (4)
1. A traditional Chinese medicine active ingredient composition with the function of increasing leucocytes is characterized in that: the traditional Chinese medicine active ingredient composition with the function of increasing the white blood cells is formed by mixing 30-50% of Ferulic Acid (FA) in angelica sinensis, 25-40% of Astragaloside (AST) in astragalus membranaceus and 15-30% of atractylenolide (AO-I) in bighead atractylodes rhizome according to the mass percentage respectively;
or is prepared by mixing Ferulic Acid (FA) in Angelica and atractylenolide I (AO-I) in Atractylodes macrocephala;
or is prepared by mixing astragaloside IV in radix astragali, i.e. AST, and atractylenolide I, i.e. AO-I, in rhizoma Atractylodis Macrocephalae.
2. The traditional Chinese medicine active ingredient composition with the effect of increasing white blood cells according to claim 1, which is characterized in that: the traditional Chinese medicine active ingredient composition with the function of increasing the white blood cells is prepared by mixing FA, AST and AO-I according to the mass ratio of 3:2: 1.
3. The traditional Chinese medicine active ingredient composition with the effect of increasing white blood cells according to claim 1, which is characterized in that: the traditional Chinese medicine active ingredient composition with the function of increasing the white blood cells is prepared by mixing FA and AO-I according to the mass ratio of 3: 1.
4. The traditional Chinese medicine active ingredient composition with the effect of increasing white blood cells according to claim 1, which is characterized in that: the traditional Chinese medicine active ingredient composition with the function of increasing the white blood cells is prepared by mixing AO-I and AST according to the mass ratio of 1: 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910665998.XA CN110327320B (en) | 2019-07-23 | 2019-07-23 | A Chinese medicinal composition with leukocyte increasing effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910665998.XA CN110327320B (en) | 2019-07-23 | 2019-07-23 | A Chinese medicinal composition with leukocyte increasing effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110327320A CN110327320A (en) | 2019-10-15 |
| CN110327320B true CN110327320B (en) | 2022-01-28 |
Family
ID=68147141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910665998.XA Active CN110327320B (en) | 2019-07-23 | 2019-07-23 | A Chinese medicinal composition with leukocyte increasing effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110327320B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1830428A (en) * | 2005-03-08 | 2006-09-13 | 诺氏制药（吉林）有限公司 | Sodium ferulate injection and its preparation method |
| CN101152232A (en) * | 2007-10-09 | 2008-04-02 | 浙江大学 | Effective component of atractylodes macrocephala, preparing method and application of the same |
| CN101642485A (en) * | 2009-08-28 | 2010-02-10 | 黑龙江省珍宝岛制药有限公司 | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura |
| WO2015131245A1 (en) * | 2014-03-03 | 2015-09-11 | La Trobe University | Sepsis treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776915B2 (en) * | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
-
2019
- 2019-07-23 CN CN201910665998.XA patent/CN110327320B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1830428A (en) * | 2005-03-08 | 2006-09-13 | 诺氏制药（吉林）有限公司 | Sodium ferulate injection and its preparation method |
| CN101152232A (en) * | 2007-10-09 | 2008-04-02 | 浙江大学 | Effective component of atractylodes macrocephala, preparing method and application of the same |
| CN101642485A (en) * | 2009-08-28 | 2010-02-10 | 黑龙江省珍宝岛制药有限公司 | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura |
| WO2015131245A1 (en) * | 2014-03-03 | 2015-09-11 | La Trobe University | Sepsis treatment |
Non-Patent Citations (2)
| Title |
|---|
| "阿魏酸治疗原因不明的白细胞减少症73例报告";冯永奎等;《重庆医药》;19781231;参见第237页左栏倒数第1段 * |
| "黄芪不同制剂对实验性白细胞减少效应的研究";徐勤娥等;《中国中西医结合杂志1995年基础理论研究特集》;19951231;参见第28页左栏第1段和参见第28页右栏第4段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110327320A (en) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The haematopoietic effect of Panax japonicus on blood deficiency model mice | |
| CN103006883A (en) | Pharmaceutical composition for treating thrombocytopenia and preparation method thereof | |
| CN110327320B (en) | A Chinese medicinal composition with leukocyte increasing effect | |
| CN102861193A (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN111920869B (en) | Traditional Chinese medicine formula for treating tumor-bearing mice by cooperating with chemotherapeutic drugs, preparation method and application | |
| CN108743600A (en) | A kind of natural drug composition and the Chinese medicine composition containing the natural drug and its application | |
| CN110638913A (en) | Yao medicine composition for treating rheumatoid arthritis and preparation method and application thereof | |
| TWI646964B (en) | Pharmaceutical composition, preparation method and use thereof for reducing side effects of cancer treatment drugs | |
| CN102357123B (en) | Application of herba dicranostigmae alcohol extract in preparing medicines for resisting melanoma transfer | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN103520222A (en) | Cordyceps militaris extractive and application thereof in preparation of medicines for treating tumors | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN104758485A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method of traditional Chinese medicine composition | |
| CN104147031A (en) | Antitumor pharmaceutical composition containing aesculin | |
| CN117159668B (en) | Application of dampness-resolving toxin-vanquishing particles in preparation of medicines for improving skeletal muscle related adverse reactions caused by dexamethasone | |
| CN110123825B (en) | Pharmaceutical composition containing demethoxydaunorubicin | |
| CN102872374B (en) | Chinese medicinal composition for assisting tumor radiotherapy | |
| CN102078409A (en) | Traditional Chinese medicine preparation for treating liver cancer | |
| Li et al. | Effects of traditional Chinese herbal medicines on blood parameters and antibody level in laying hens | |
| CN102908405B (en) | Traditional Chinese medicine composition of reversing tumor multi-drug resistance (MDR) and preparation method thereof | |
| CN109620911B (en) | Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof | |
| CN106265669A (en) | Daidzein and the drug regimen of 10 hydroxy camptothecins and application thereof | |
| CN102716382A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof | |
| CN104324041A (en) | Novel compound medicine for auxiliary treatments on liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240126 Address after: 410205 No. 339 tongzipo West Road, high tech Zone, Changsha City, Hunan Province Patentee after: JIUZHITANG Co.,Ltd. Country or region after: China Address before: 030006 No. 92, Hollywood Road, Taiyuan, Shanxi Patentee before: SHANXI University Country or region before: China |